神经元级可解释的人工智能对阿尔茨海默氏病的评估从 fundus 图像
Nooshin Yousefzadeh1, Charlie Tran2, Adolfo Ramirez-Zamora3
1Department of Computer and Information Science and Engineering, University of Florida, Gainesville, Florida, USA.
Scientific reports
|April 2, 2024
概括
研究人员开发了LAVA,这是一种分析视网膜图像以检测阿尔茨海默病 (AD) 阶段的AI工具. 这种可解释的AI验证了视网膜血管作为早期AD检测和进展监测的诊断生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 眼科医生 眼科 眼科
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,也是痴呆的主要原因.
- 早期诊断AD对于及时干预和治疗至关重要.
- 视网膜与大脑的解剖联系使其成为AD检测的潜在地点.
研究的目的:
- 通过使用视网膜成像来检测阿尔茨海默氏症的新型,模型不可知可解释的AI框架 (LAVA).
- 从视网膜图像直接评估AD进展的连续性,没有纵向或临床数据.
- 为了验证视网膜血管作为AD诊断和分期的生物标志物.
主要方法:
- 开发了LAVA,一个可解释的AI框架,探讨卷积神经网络 (CNN) 模型的中间层.
- 利用视网膜成像数据来评估AD的阶段.
- 利用英国生物库的认知测试和血管形态特征进行验证.
主要成果:
- 通过LAVA,可以有效地识别阿尔茨海默氏病在整个进展连续的各个阶段.
- 该框架为其诊断决策提供了合理的解释.
- 视网膜血管系统被验证为AD评估的有前途的生物标志物.
结论:
- 拉瓦框架为早期阿尔茨海默病检测和分期使用视网膜成像提供了一种新的方法.
- 可解释的人工智能可以提高神经退行性疾病视网膜成像的诊断能力.
- 视网膜血管系统作为阿尔茨海默病的非侵入性诊断方式具有显著的潜力.
相关概念视频
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184


